Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)
Status:
Completed
Trial end date:
2015-09-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to further evaluate the effects that eltrombopag (and
romiplostim) have on platelets in subjects with chronic ITP. Eltrombopag is approved by the
Food and Drug Administration (FDA) for the treatment of low platelets in patients with
chronic ITP. It is being further studied by GlaxoSmithKline (now Novartis) in other
conditions associated with low platelets. This research study is being done because
eltrombopag has been shown to increase platelet counts in a different way than other
therapies for ITP. The investigators want to further study how eltrombopag and romiplostim
affect subjects and their platelets to determine how the study drug should best be used in
ITP treatment.